NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NYSEMKT:NNVC
- CUSIP: N/A
- Web: N/A
- Market Cap: $82.92 million
- Outstanding Shares: 62,819,000
- 50 Day Moving Avg: $1.16
- 200 Day Moving Avg: $1.18
- 52 Week Range: $1.03 - $2.04
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 33.00
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.33 per share
- Price / Book: 4.00
- Average Volume: 66,655 shs.
- Beta: 0.44
- Short Ratio: 30.62
Frequently Asked Questions for NanoViricides (NYSEMKT:NNVC)
What is NanoViricides' stock symbol?
NanoViricides trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NNVC."
How were NanoViricides' earnings last quarter?
NanoViricides Inc (NYSEMKT:NNVC) released its earnings results on Wednesday, February, 25th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.02. The company earned $1.82 million during the quarter, compared to analysts' expectations of $1.75 million. View NanoViricides' Earnings History.
Who are some of NanoViricides' key competitors?
Some companies that are related to NanoViricides include Peregrine Pharmaceuticals (PPHM), Asterias Biotherapeutics (AST), Recro Pharma (REPH), Athersys (ATHX), Kindred Biosciences (KIN), Strongbridge Biopharma plc (SBBP), Obalon Therapeutics (OBLN), Vascular Biogenics Ltd (VBLT), Concord Medical Services Hldg Ltd (CCM), ADOCIA SPON ADR REPR 1 (ADOCY), Synthetic Biologics (SYN), Mediwound Ltd (MDWD), Fate Therapeutics (FATE), Uniqure NV (QURE), Fluidigm (FLDM), Alliance HealthCare Services (AIQ), Helius Medical Technologies (HSDT) and Summit Therapeutics PLC (SMMT).
How do I buy NanoViricides stock?
Shares of NanoViricides can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of NanoViricides stock cost?
One share of NanoViricides stock can currently be purchased for approximately $1.32.
Consensus Ratings for NanoViricides (NYSEMKT:NNVC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for NanoViricides (NYSEMKT:NNVC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for NanoViricides (NYSEMKT:NNVC)Earnings History by Quarter for NanoViricides (NYSEMKT:NNVC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/25/2015||Q215||($0.05)||($0.03)||$1.75 million||$1.82 million||View||N/A|
Earnings Estimates for NanoViricides (NYSEMKT:NNVC)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $0.04 EPS
Dividend History for NanoViricides (NYSEMKT:NNVC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NanoViricides (NYSEMKT:NNVC)Insider Trades by Quarter for NanoViricides (NYSEMKT:NNVC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/22/2015||Milton Boniuk||Director||Buy||25,000||$1.30||$32,500.00|| |
|9/11/2015||Milton Boniuk||Director||Buy||50,000||$1.02||$51,000.00|| |
|8/26/2015||Milton Boniuk||Director||Buy||50,000||$1.05||$52,500.00|| |
|7/8/2015||Milton Boniuk||Director||Buy||50,000||$1.58||$79,000.00|| |
|5/20/2015||Milton Boniuk||Director||Buy||50,000||$1.60||$80,000.00|| |
|5/8/2015||Milton Boniuk||Director||Buy||405,954||$2.58||$1,047,361.32|| |
|1/12/2015||Anil Diwan||Major Shareholder||Buy||14,000||$2.56||$35,840.00|| |
|1/6/2015||Milton Boniuk||Director||Buy||25,000||$2.60||$65,000.00|| |
|12/9/2014||Milton Boniuk||Director||Buy||50,000||$3.05||$152,500.00|| |
|7/17/2014||Milton Boniuk||Director||Buy||57,144||$3.50||$200,004.00|| |
|2/20/2014||Anil Diwan||Major Shareholder||Buy||50,000||$3.61||$180,500.00|| |
|10/21/2013||Anil Diwan||Major Shareholder||Sell||142,000||$5.29||$751,180.00|| |
Headline Trends for NanoViricides (NYSEMKT:NNVC)
Latest Headlines for NanoViricides (NYSEMKT:NNVC)